64Cu-FBP8 for Alzheimer Disease

Phase-Based Progress Estimates
Massachusetts General Hospital, Boston, MA
Alzheimer Disease+2 More
64Cu-FBP8 - Drug
All Sexes
What conditions do you have?

Study Summary

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

Eligible Conditions

  • Alzheimer Disease
  • Alzheimer's Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer Disease

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: baseline

Concentration of fibrin in the brains of ADRD subjects and healthy controls

Trial Safety

Safety Progress

1 of 3

Other trials for Alzheimer Disease

Trial Design

1 Treatment Group

Cognitively Normal Subjects and ADRD subjects
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: 64Cu-FBP8 · No Placebo Group · Phase 1 & 2

Cognitively Normal Subjects and ADRD subjectsExperimental Group · 2 Interventions: PET/MR Imaging, 64Cu-FBP8 · Intervention Types: DiagnosticTest, Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital 1Photo of Massachusetts General Hospital 2Photo of Massachusetts General Hospital 3
1993First Recorded Clinical Trial
28 TrialsResearching Alzheimer Disease
2427 CompletedClinical Trials

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,555 Previous Clinical Trials
46,915,159 Total Patients Enrolled
2 Trials studying Alzheimer Disease
3,304 Patients Enrolled for Alzheimer Disease
Massachusetts General HospitalLead Sponsor
2,660 Previous Clinical Trials
30,828,767 Total Patients Enrolled
19 Trials studying Alzheimer Disease
198,591 Patients Enrolled for Alzheimer Disease
Ciprian Catana, MD, PhDPrincipal InvestigatorMassachusetts General Hospital

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to provide informed consent.
You have a clinical diagnosis of AD, either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.